CDK4/6 dual inhibitor abemaciclib demonstrates compelling...

CDK4/6 dual inhibitor abemaciclib demonstrates compelling preclinical activity against esophageal adenocarcinoma: a novel therapeutic option for a deadly disease

Kosovec, Juliann E., Zaidi, Ali H., Omstead, Ashten N., Matsui, Daisuke, Biedka, Mark J., Cox, Erin J., Campbell, Patrick T., Biederman, Robert W.W., Kelly, Ronan J., Jobe, Blair A.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
8
Language:
english
Journal:
Oncotarget
DOI:
10.18632/oncotarget.22244
Date:
November, 2017
File:
PDF, 3.09 MB
english, 2017
Conversion to is in progress
Conversion to is failed